Immunotherapy for Metastatic Cancer

My current research interest is to develop effective immunotherapy for treating metastatic cancer and to investigate the mechanisms underlying the treatment efficacy. Our focus is to combine adoptive autologous natural killer (NK) cell therapy with clinically used chemical drugs to overcome the tumor-induced immunosuppression and to trigger effective type 1 anti-tumor immune responses. For studying NK cell therapy in spontaneous metastasis, we established a method to expand NK cells with anti-tumor activities and a syngeneic orthotopic breast cancer resection and metastasis model that mimics cancer recurrence at distal site in patients after primary tumor resection. We found that the autologous NK cell therapy promotes long-term survival of tumor-resected mice with low metastatic burden and induces protective tumor-specific T cell memory. For developing treatment for high tumor burden cancer, we identified chemical drug therapies that show differential efficacy between tumor-bearing mice of different strains. Based on these findings, we aim to investigate (1) the modulation of the metastatic microenvironment by the NK cell therapy, and how it affects tumor-specific T cell response, and (2) the mechanisms underlying the drugs’ differential efficacy in different tumor models.

Thumb
Liao, Nan-Shih